Dunedin-based Pacific Edge said today that its research paper on Cxbladder Triage had now been published in the internationally leading medical journal BioMed Central (“BMC”) Urology.

Chief Executive David Darling said: “This is a significant milestone for the company as it profiles our latest bladder cancer product to a global audience.” 

The research paper can be viewed by clicking on the following link:

http://www.biomedcentral.com/content/pdf/s12894-015-0018-5.pdf

“Publication in BMC Urology is an open access journal, available online, and as such is a quick and efficient way of reaching a large international audience including the people who make treatment decisions for patients and for the payers who fund such treatment. It is also part of our strategy of making the product available in the USA this year,” David Darling added.

Cxbladder Triage, the second product in its suite of diagnostic tests for the detection and management of bladder cancer, was launched at the end of last year in New Zealand. “It takes us a step closer to our vision of a ‘one-stop-shop’ for bladder cancer detection and management,” says David Darling.

Cxbladder Triage complements the first molecular diagnostic test Cxbladder Detect and will enable clinicians and physicians to accurately segregate patients who present with hematuria, who have a low probability of having bladder cancer. Potentially this will save many patients from undergoing an expensive and invasive investigation for bladder cancer.